While the soluble, truncated form of TRAIL has a short half-life in the bloodstream and bears the risk of inducing resistance, MSCs as delivery vehicles allow a continuous expression of the full-length form of TRAIL at the tumor site. The gene discussed is TNFSF10; the disease is neoplasm.